CSPC Pharmaceutical's (HKG:1093) CPO301 has been granted the third Fast Track designation by the US Food and Drug Administration (FDA) for lung cancer patients, a Monday Hong Kong bourse filing said.
In particular, the designation is for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
"The Fast Track designations in all subtypes of NSCLC were granted based on promising clinical efficacy data," said CSPC.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。